2024
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. DOI: 10.1016/j.jlb.2024.100168.Peer-Reviewed Original ResearchTriple negative breast cancerResidual cancer burdenCirculating tumor DNANegative breast cancerPathological responsePost-NACBreast cancerPlasma circulating tumor DNATriple negative breast cancer patientsResidual cancer burden scoreCirculating tumour DNA fractionPost-neoadjuvant chemotherapyPre-NAC samplesWeekly nab-paclitaxelTumor DNA methylation profilesTumor DNA fractionHot spot mutationsYouden's J statisticNab-paclitaxelPre-NACTumor variantsTumor DNATumor fractionClinical trialsDNA methylation profilesPeripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer
Foldi J, Blenman K, Marczyk M, Gunasekharan V, Polanska A, Gee R, Davis M, Kahn A, Silber A, Pusztai L. Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 369-377. PMID: 39002068, DOI: 10.1007/s10549-024-07426-3.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerAssociated with pathological responsePathological complete responseNeoadjuvant chemotherapyCytokine levelsPathological responseAdverse eventsBreast cancerEarly-stage triple-negative breast cancerPatients treated with immune checkpoint inhibitorsB cell clonal expansionMeasured serum cytokine levelsImmune checkpoint inhibitorsGM-CSF levelsPeripheral blood cytokine levelsBlood cytokine levelsSerum cytokine levelsB cell receptorMagnetic bead panelBenjamini-Hochberg correctionSample of patientsImmunoSEQ platformCheckpoint inhibitorsComplete response
2012
A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PLOS ONE 2012, 7: e49529. PMID: 23185353, PMCID: PMC3504014, DOI: 10.1371/journal.pone.0049529.Peer-Reviewed Original ResearchConceptsMulti-gene predictorsPatients' clinical outcomesClinical outcomesCancer patientsTherapeutic responseStandard combination chemotherapyBreast cancer patientsClinical outcome measurementsPatient's therapeutic responseBreast cancer cell linesCancer cell linesNegative patientsCombination chemotherapyPatient cohortPathological responseBreast cancerEstrogen receptorClinical utilityOutcome measurementsChemotherapyPatientsCell linesOutcomesPredictorsCOXEN
2007
Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients
Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans W, Zerba K, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. Journal Of Clinical Oncology 2007, 25: 2525-2525. DOI: 10.1200/jco.2007.25.18_suppl.2525.Peer-Reviewed Original ResearchBreast cancer patientsER patientsCancer patientsPredictive markerClinical trialsPaclitaxel activityER-negative breast cancer patientsComplete pathological responseER-negative patientsTaxane-containing regimensTaxane-containing therapyExpression levelsIxabepilone treatmentPatient selectionBC patientsPathological responseIxabepilonePatientsTherapeutic valueProtein 3SiRNA studiesDifferential markersROC curveTrialsCandidate markers
2006
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy. Cancer 2006, 109: 496-501. PMID: 17149760, DOI: 10.1002/cncr.22418.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCyclophosphamideEpirubicinFemaleFluorouracilHumansKineticsMiddle AgedNeoadjuvant TherapyPrognosisProspective StudiesReceptor, ErbB-2TrastuzumabConceptsPrimary breast cancerPathological complete responseBreast cancerECD levelsPrimary chemotherapyNeoadjuvant therapyPathological responseWeek 6HER-2 extracellular domainWeek 3HER-2/neu receptorCycles of fluorouracilCycles of paclitaxelNeu extracellular domainTrastuzumab-based regimensUtility of quantitationInitiation of chemotherapyExtracellular domainSame chemotherapyWeekly trastuzumabInitial chemotherapyNeoadjuvant chemotherapyComplete responseTreatment regimenResidual disease
2004
Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer
Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation 2004, 22: 248-256. PMID: 15199607, DOI: 10.1081/cnv-120030213.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarrier ProteinsCell DeathChemotherapy, AdjuvantDNA-Binding ProteinsDoxorubicinFemaleHumansImmunohistochemistryMiddle AgedNeoadjuvant TherapyPredictive Value of TestsPrognosisProto-Oncogene Proteins c-bcl-2Transcription FactorsTreatment OutcomeConceptsComplete pathological responsePathological responseBcl-2 expressionNeoplastic cellsBcl-2Breast cancerTissue specimensSubsequent pathological responsesAdvanced breast cancerBAG-1Breast epithelial cellsBAG-1 expressionExploratory pilot studyPrechemotherapy specimensNeoadjuvant chemotherapyClinical responseResidual tumorCytotoxic therapyPosttreatment specimensAnti-apoptotic proteinsPreoperative doxorubicinChemotherapyCytoplasmic stainingIndividual tumorsBreast tissue
2002
Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer
Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. The Cancer Journal 2002, 8: 461-468. PMID: 12500855, DOI: 10.1097/00130404-200211000-00010.Peer-Reviewed Original ResearchConceptsCore biopsy specimensBiopsy specimensBreast cancerNeoadjuvant chemotherapyGlobal gene expression changesGene expression changesGood pathological responsePrimary breast cancerExpression changesHuman breast cancerHuman solid tumorsPoor respondersPosttreatment specimensPathological responseIndividual patientsChemotherapyPatientsSerial samplesSolid tumorsExpression profilesIndividual tumorsPretreatment samplesDifferent tumorsTumorsDifferent patients